These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38353183)

  • 1. DBS are suitable for 1,5-anhydroglucitol monitoring in GSD1b and G6PC3-deficient patients taking SGLT2 inhibitors to treat neutropenia.
    Dewulf JP; Chevalier N; Marie S; Veiga-da-Cunha M
    Mol Genet Metab; 2023 Nov; 140(3):107712. PubMed ID: 38353183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5.
    Boulanger C; Stephenne X; Diederich J; Mounkoro P; Chevalier N; Ferster A; Van Schaftingen E; Veiga-da-Cunha M
    J Inherit Metab Dis; 2022 Jul; 45(4):759-768. PubMed ID: 35506446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT5 is the renal transporter for 1,5-anhydroglucitol, a major player in two rare forms of neutropenia.
    Diederich J; Mounkoro P; Tirado HA; Chevalier N; Van Schaftingen E; Veiga-da-Cunha M
    Cell Mol Life Sci; 2023 Aug; 80(9):259. PubMed ID: 37594549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of the Neutropenia Associated with GSD1b and G6PC3 Deficiency with SGLT2 Inhibitors.
    Veiga-da-Cunha M; Wortmann SB; Grünert SC; Van Schaftingen E
    Diagnostics (Basel); 2023 May; 13(10):. PubMed ID: 37238286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SLGT2 Inhibitor Rescues Myelopoiesis in G6PC3 Deficiency.
    Hiwarkar P; Bargir U; Pandrowala A; Bodhanwala M; Thakker N; Taur P; Madkaikar M; Desai M
    J Clin Immunol; 2022 Nov; 42(8):1653-1659. PubMed ID: 35838821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency.
    Veiga-da-Cunha M; Chevalier N; Stephenne X; Defour JP; Paczia N; Ferster A; Achouri Y; Dewulf JP; Linster CL; Bommer GT; Van Schaftingen E
    Proc Natl Acad Sci U S A; 2019 Jan; 116(4):1241-1250. PubMed ID: 30626647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients.
    Hexner-Erlichman Z; Veiga-da-Cunha M; Zehavi Y; Vadasz Z; Sabag AD; Tatour S; Spiegel R
    Front Pediatr; 2022; 10():1071464. PubMed ID: 36507137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor.
    Wortmann SB; Van Hove JLK; Derks TGJ; Chevalier N; Knight V; Koller A; Oussoren E; Mayr JA; van Spronsen FJ; Lagler FB; Gaughan S; Van Schaftingen E; Veiga-da-Cunha M
    Blood; 2020 Aug; 136(9):1033-1043. PubMed ID: 32294159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre.
    Halligan RK; Dalton RN; Turner C; Lewis KA; Mundy HR
    Orphanet J Rare Dis; 2022 May; 17(1):195. PubMed ID: 35549996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes.
    Chou JY; Jun HS; Mansfield BC
    J Inherit Metab Dis; 2015 May; 38(3):511-9. PubMed ID: 25288127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical spectrum, over 12-year follow-up and experience of SGLT2 inhibitors treatment on patients with glycogen storage disease type Ib: a single-center retrospective study.
    Shao YX; Liang CL; Su YY; Lin YT; Lu ZK; Lin RZ; Zhou ZZ; Zeng CH; Tao CY; Liu ZC; Zhang W; Liu L
    Orphanet J Rare Dis; 2024 Apr; 19(1):155. PubMed ID: 38605407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of glucose recycling between endoplasmic reticulum and cytoplasm underlies cellular dysfunction in glucose-6-phosphatase-beta-deficient neutrophils in a congenital neutropenia syndrome.
    Jun HS; Lee YM; Cheung YY; McDermott DH; Murphy PM; De Ravin SS; Mansfield BC; Chou JY
    Blood; 2010 Oct; 116(15):2783-92. PubMed ID: 20498302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical and molecular review of ubiquitous glucose-6-phosphatase deficiency caused by G6PC3 mutations.
    Banka S; Newman WG
    Orphanet J Rare Dis; 2013 Jun; 8():84. PubMed ID: 23758768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshop.
    Grünert SC; Derks TGJ; Mundy H; Dalton RN; Donadieu J; Hofbauer P; Jones N; Uçar SK; LaFreniere J; Contreras EL; Pendyal S; Rossi A; Schneider B; Spiegel R; Stepien KM; Wesol-Kucharska D; Veiga-da-Cunha M; Wortmann SB
    Mol Genet Metab; 2024 Mar; 141(3):108144. PubMed ID: 38277989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib.
    Grünert SC; Elling R; Maag B; Wortmann SB; Derks TGJ; Hannibal L; Schumann A; Rosenbaum-Fabian S; Spiekerkoetter U
    Orphanet J Rare Dis; 2020 Aug; 15(1):218. PubMed ID: 32838757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel mutation of SLC37A4 in a glycogen storage disease type Ib patient with neutropenia, horseshoe kidney, and arteriovenous malformation: a case report.
    Meimand SE; Azizi G; Yazdani R; Sanadgol N; Rezaei N
    Immunol Res; 2023 Feb; 71(1):107-111. PubMed ID: 36129616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and characterization of an inducible mouse model for glycogen storage disease type Ib.
    Raggi F; Pissavino AL; Resaz R; Segalerba D; Puglisi A; Vanni C; Antonini F; Del Zotto G; Gamberucci A; Marcolongo P; Bosco MC; Grillo F; Mastracci L; Eva A
    J Inherit Metab Dis; 2018 Nov; 41(6):1015-1025. PubMed ID: 29967951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G6PC3 mutations are associated with a major defect of glycosylation: a novel mechanism for neutrophil dysfunction.
    Hayee B; Antonopoulos A; Murphy EJ; Rahman FZ; Sewell G; Smith BN; McCartney S; Furman M; Hall G; Bloom SL; Haslam SM; Morris HR; Boztug K; Klein C; Winchester B; Pick E; Linch DC; Gale RE; Smith AM; Dell A; Segal AW
    Glycobiology; 2011 Jul; 21(7):914-24. PubMed ID: 21385794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis.
    McDermott DH; De Ravin SS; Jun HS; Liu Q; Priel DA; Noel P; Takemoto CM; Ojode T; Paul SM; Dunsmore KP; Hilligoss D; Marquesen M; Ulrick J; Kuhns DB; Chou JY; Malech HL; Murphy PM
    Blood; 2010 Oct; 116(15):2793-802. PubMed ID: 20616219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycogen storage disease type Ib neutrophils exhibit impaired cell adhesion and migration.
    Kim GY; Lee YM; Kwon JH; Jun HS; Chou J
    Biochem Biophys Res Commun; 2017 Jan; 482(4):569-574. PubMed ID: 27864142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.